Company’s 36-month beta value is 0.41.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 4 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for KPTI is 7.66M, and currently, short sellers hold a 18.09% ratio of that floaft. The average trading volume of KPTI on March 10, 2025 was 88.47K shares.
KPTI) stock’s latest price update
Karyopharm Therapeutics Inc (NASDAQ: KPTI)’s stock price has soared by 10.77 in relation to previous closing price of 6.22. Nevertheless, the company has seen a loss of -13.33% in its stock price over the last five trading days. prnewswire.com reported 2025-03-05 that – XPOVIO ® is the first and only approved XPO1 inhibitor in Indonesia. – From the second half of 2024 to now, XPOVIO ® was successively approved in Thailand, Malaysia and Indonesia, significantly expanding Antengene’s commercial presence in APAC.
KPTI’s Market Performance
Karyopharm Therapeutics Inc (KPTI) has experienced a -13.33% fall in stock performance for the past week, with a -31.65% drop in the past month, and a -43.29% drop in the past quarter. The volatility ratio for the week is 12.79%, and the volatility levels for the past 30 days are at 11.26% for KPTI. The simple moving average for the past 20 days is -17.98% for KPTI’s stock, with a -42.73% simple moving average for the past 200 days.
Analysts’ Opinion of KPTI
Many brokerage firms have already submitted their reports for KPTI stocks, with Piper Sandler repeating the rating for KPTI by listing it as a “Overweight.” The predicted price for KPTI in the upcoming period, according to Piper Sandler is $8 based on the research report published on January 19, 2023 of the previous year 2023.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see KPTI reach a price target of $10, previously predicting the price at $7. The rating they have provided for KPTI stocks is “Outperform” according to the report published on November 04th, 2022.
JP Morgan gave a rating of “Neutral” to KPTI, setting the target price at $8 in the report published on February 09th of the previous year.
KPTI Trading at -27.41% from the 50-Day Moving Average
After a stumble in the market that brought KPTI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.98% of loss for the given period.
Volatility was left at 11.26%, however, over the last 30 days, the volatility rate increased by 12.79%, as shares sank -30.09% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.66% lower at present.
During the last 5 trading sessions, KPTI fell by -13.33%, which changed the moving average for the period of 200-days by -60.06% in comparison to the 20-day moving average, which settled at $8.40. In addition, Karyopharm Therapeutics Inc saw -32.08% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KPTI starting from Cheng Sohanya Roshan, who sale 3,445 shares at the price of $6.29 back on Mar 04 ’25. After this action, Cheng Sohanya Roshan now owns 34,314 shares of Karyopharm Therapeutics Inc, valued at $21,669 using the latest closing price.
Paulson Richard A., the President and CEO of Karyopharm Therapeutics Inc, sale 11,694 shares at $6.29 during a trade that took place back on Mar 04 ’25, which means that Paulson Richard A. is holding 82,984 shares at $73,555 based on the most recent closing price.
Stock Fundamentals for KPTI
Current profitability levels for the company are sitting at:
- -0.82 for the present operating margin
- 0.96 for the gross margin
The net margin for Karyopharm Therapeutics Inc stands at -0.53. The total capital return value is set at -1.66.
Based on Karyopharm Therapeutics Inc (KPTI), the company’s capital structure generated 22.87 points at debt to capital in total, while cash flow to debt ratio is standing at -0.66. The debt to equity ratio resting at -1.05. The interest coverage ratio of the stock is -3.19.
Currently, EBITDA for the company is -38.6 million with net debt to EBITDA at -3.42. When we switch over and look at the enterprise to sales, we see a ratio of 1.31. The receivables turnover for the company is 4.72for trailing twelve months and the total asset turnover is 0.88. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.70.
Conclusion
In a nutshell, Karyopharm Therapeutics Inc (KPTI) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
